Week In Review: Hengrui And Dearon Announce $7.2B In Drug Licensings
Evgenii Kovalev Deals and Financings Jiangsu Hengrui Medicine out-licensed global rights for its portfolio of three proprietary GLP-1 candidates to a US startup, Hercules, in a deal worth up to $6 billion. Hengrui will receive $110 million upfront, up to $ …